RxDoctor Payments DataLook up a doctor →

Iffat Ahmed, DO

Internal Medicine · Naperville, ILNPI 1063668192

Payments from drug & device makers

$186,002in general payments, 2019–2025

Across 711 payments — averaging $261.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$176K
  • Novo Nordisk$2K
  • Boehringer Ingelheim$2K
  • AbbVie$2K
  • Bayer$1K
  • Currax Pharmaceuticals LLC$552
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$8,0504%
  • Speaking & faculty fees$140,26375%
  • Travel & lodging$24,85313%
  • Food & beverage$12,8287%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$186,002 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$76,776
Medicare patients
116
Services billed
1,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide271$313,693
WegovySemaglutide67$94,497
OzempicSemaglutide40$47,920
TrulicityDulaglutide17$21,206
Repatha SyringeEvolocumab11$6,165
Naltrexone Hcl47$2,745
Bupropion Hcl33$2,052
Bupropion XlBupropion Hcl112$2,014
Metformin Hcl ErMetformin Hcl146$1,426
Ezetimibe40$1,172
Topiramate80$688
Atorvastatin Calcium63$458
Rosuvastatin Calcium39$300
Metformin Hcl11$211
Ondansetron Hcl55$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$175,509$334,900288 claims
Novo NordiskWegovy, Ozempic$2,475$142,417107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →